Shuai Cao

Title(s)Postdoctoral Scholar - Research Associate
SchoolKeck School of Medicine of Usc
Address1450 Biggy Street
Health Sciences Campus
Los Angeles CA 90033
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. Sci Rep. 2021 06 09; 11(1):12191. Naseem M, Cao S, Yang D, Millstein J, Puccini A, Loupakis F, Stintzing S, Cremolini C, Tokunaga R, Battaglin F, Soni S, Berger MD, Barzi A, Zhang W, Falcone A, Heinemann V, Lenz HJ. PMID: 34108518; PMCID: PMC8190302.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. Cancer Genomics Proteomics. 2021 May-Jun; 18(3):317-324. Suenaga M, Zhang WU, Mashima T, Schirripa M, Cao S, Okazaki S, Berger MD, Miyamoto Y, Barzi A, Yamaguchi T, Lenz HJ. PMID: 33893084; PMCID: PMC8126324.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Mol Cancer Ther. 2021 06; 20(6):1153-1160. Arai H, Cao S, Battaglin F, Wang J, Kawanishi N, Tokunaga R, Loupakis F, Stintzing S, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. PMID: 33785650.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics J. 2021 06; 21(3):285-295. Suenaga M, Schirripa M, Cao S, Zhang W, Cremolini C, Lonardi S, Okazaki S, Berger MD, Miyamoto Y, Soni S, Barzi A, Yamaguchi T, Loupakis F, Falcone A, Lenz HJ. PMID: 33542444.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    5. Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. Pharmacogenet Genomics. 2021 01; 31(1):10-16. Suenaga M, Cao S, Zhang W, Matsusaka S, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Barzi A, Yamamoto N, Yamaguchi T, Lenz HJ. PMID: 32732498; PMCID: PMC7655616.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    6. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers (Basel). 2020 Oct 13; 12(10). Volz NB, Hanna DL, Stintzing S, Zhang W, Yang D, Cao S, Ning Y, Matsusaka S, Sunakawa Y, Berger MD, Cremolini C, Loupakis F, Falcone A, Lenz HJ. PMID: 33065994; PMCID: PMC7601940.
      View in: PubMed   Mentions: 1  
    7. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS One. 2020; 15(9):e0239439. Miyamoto Y, Schirripa M, Suenaga M, Cao S, Zhang W, Okazaki S, Berger MD, Matsusaka S, Yang D, Ning Y, Baba H, Loupakis F, Lonardi S, Pietrantonio F, Borelli B, Cremolini C, Yamaguchi T, Lenz HJ. PMID: 32970737; PMCID: PMC7514061.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers (Basel). 2020 Jun 30; 12(7). Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Murgioni S, Lonardi S, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Barzi A, Loupakis F, Falcone A, Lenz HJ. PMID: 32629861; PMCID: PMC7408001.
      View in: PubMed   Mentions: 2  
    9. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. Eur J Cancer. 2020 05; 131:89-97. Berger MD, Ning Y, Stintzing S, Heinemann V, Cao S, Zhang W, Yang D, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Tokunaga R, Naseem M, Battaglin F, Cremolini C, Falcone A, Loupakis F, Lenz HJ. PMID: 32305727; PMCID: PMC7513926.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    10. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Cancer Sci. 2020 Feb; 111(2):441-450. Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz HJ. PMID: 31821662; PMCID: PMC7004533.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    11. The Cancer Bell: Too Much of a Good Thing? Int J Radiat Oncol Biol Phys. 2019 10 01; 105(2):247-253. Williams PA, Hu J, Yang D, Cao S, Jennelle RL. PMID: 31300336.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Patient-reported outcomes of the relative severity of side effects from cancer radiotherapy. Support Care Cancer. 2020 Jan; 28(1):309-316. Williams PA, Cao S, Yang D, Jennelle RL. PMID: 31044307.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    13. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. Int J Cancer. 2019 10 15; 145(8):2082-2090. Tokunaga R, Cao S, Naseem M, Battaglin F, Lo JH, Arai H, Loupakis F, Stintzing S, Puccini A, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. PMID: 30856283; PMCID: PMC7491977.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    14. Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. Eur J Cancer. 2019 04; 111:138-147. Puccini A, Loupakis F, Stintzing S, Cao S, Battaglin F, Togunaka R, Naseem M, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. PMID: 30852420; PMCID: PMC6436973.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    15. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. Int J Cancer. 2019 05 15; 144(10):2567-2577. Suenaga M, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Yamaguchi T, Lenz HJ. PMID: 30411783; PMCID: PMC7497849.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. Eur J Cancer. 2019 01; 107:100-114. Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ. PMID: 30554073; PMCID: PMC6367121.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    17. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. Clin Colorectal Cancer. 2019 03; 18(1):e8-e19. Tokunaga R, Cao S, Naseem M, Lo JH, Battaglin F, Puccini A, Berger MD, Soni S, Millstein J, Zhang W, Stintzing S, Loupakis F, Cremolini C, Heinemann V, Falcone A, Lenz HJ. PMID: 30293873; PMCID: PMC6416082.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    18. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics J. 2018 09; 18(5):623-632. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Lonardi S, Bergamo F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ. PMID: 29925895; PMCID: PMC6151284.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    19. Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. Clin Colorectal Cancer. 2018 09; 17(3):215-222.e3. McSkane M, Stintzing S, Heinemann V, Puccini A, Naseem M, Cao S, Lenz HJ, Jelas I. PMID: 29880436; PMCID: PMC7496217.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    20. NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One. 2018; 13(3):e0193640. Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ. PMID: 29522543; PMCID: PMC5844536.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clin Colorectal Cancer. 2018 06; 17(2):e395-e414. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz HJ. PMID: 29606345; PMCID: PMC7493703.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    22. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clin Cancer Res. 2018 02 15; 24(4):784-793. Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ. PMID: 29208668; PMCID: PMC7505162.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    23. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer. 2017 11; 86:197-206. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, Salvatore L, Borelli B, Pietrantonio F, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ. PMID: 28992563; PMCID: PMC7497848.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    24. Improvement in the Outcomes of MELD ≥ 40 Liver Transplantation: An Analysis of 207 Consecutive Transplants in a Highly Competitive DSA. Transplantation. 2017 10; 101(10):2360-2367. Nekrasov V, Matsuoka L, Kaur N, Pita A, Whang G, Cao S, Groshen S, Alexopoulos S. PMID: 28319564.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. Colorectal cancer: epigenetic alterations and their clinical implications. Biochim Biophys Acta Rev Cancer. 2017 Dec; 1868(2):439-448. Puccini A, Berger MD, Naseem M, Tokunaga R, Battaglin F, Cao S, Hanna DL, McSkane M, Soni S, Zhang W, Lenz HJ. PMID: 28939182; PMCID: PMC5757873.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    26. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer. 2017 Nov 15; 123(22):4506-4514. Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD, Miyamoto Y, Suenaga M, Iqubal S, Barzi A, Cremolini C, Falcone A, Battaglin F, Salvatore L, Borelli B, Helentjaris TG, Lenz HJ. PMID: 28708932; PMCID: PMC5673544.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    27. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer. 2017 09 15; 141(6):1222-1230. Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ. PMID: 28569041; PMCID: PMC5528002.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    28. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. Int J Cancer. 2017 07 15; 141(2):383-392. Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ. PMID: 28369940; PMCID: PMC5510747.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    29. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. Eur J Cancer. 2017 05; 77:13-20. Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ. PMID: 28347919; PMCID: PMC7497847.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    30. Effects of recipient size and allograft type on pediatric liver transplantation for biliary atresia. Liver Transpl. 2017 02; 23(2):221-233. Alexopoulos SP, Nekrasov V, Cao S, Groshen S, Kaur N, Genyk YS, Matsuoka L. PMID: 27862929.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    31. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. Mol Cancer Ther. 2016 07; 15(7):1740-5. Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ. PMID: 27196764; PMCID: PMC4936942.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    32. Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer. Cancer Biol Ther. 2016 07 02; 17(7):751-9. Sunakawa Y, Yang D, Moran M, Astrow SH, Tsuji A, Stephens C, Zhang W, Cao S, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Masuishi T, Takeuchi M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ. PMID: 27104867; PMCID: PMC4970538.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    33. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Mol Cancer Ther. 2016 06; 15(6):1405-11. Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W, Mizunuma N, Lenz HJ. PMID: 26983880; PMCID: PMC4893985.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    34. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clin Cancer Res. 2016 07 01; 22(13):3218-26. Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ. PMID: 26839145; PMCID: PMC4930688.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    35. Kidney transplantation in the Hispanic population. Clin Transplant. 2016 Feb; 30(2):118-23. Matsuoka L, Alicuben E, Woo K, Cao S, Groshen S, Qazi Y, Smogorzewski M, Selby R, Alexopoulos S. PMID: 26529140.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Shuai's Networks
    Concepts (181)
    Derived automatically from this person's publications.
    _
    Co-Authors (13)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _